[French] Pharmaceutical specialties based on rituximab IV

Auto-translated from French

Original title: Spécialités pharmaceutiques à base de rituximab IV

Healthcare Public Procurement (HeCaPP)

Published: Oct 7, 2026

Updated: Oct 7, 2026

Source: belgium_eprocurement

About This Opportunity

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Belgium, Europe, this opportunity is open to firms and consortiums.

Published through Belgium e-Procurement, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.

Description

Original language: French

This tender, originating from Belgium and sourced via belgium_eprocurement, pertains to the procurement of pharmaceutical specialties based on rituximab IV. The contracting authority is seeking a reliable supply of this specific biologic medication for therapeutic use. The procurement type is for the acquisition of specialized medical goods. Typical requirements for such a tender would include stringent adherence to pharmaceutical quality standards, regulatory compliance (e.g., Good Manufacturing Practices - GMP), and specific product specifications for rituximab IV, including concentration, volume, formulation, and packaging. Bidders will need to demonstrate their authorization to market and distribute pharmaceutical products within Belgium and the European Union, provide detailed product information, including Certificates of Analysis, and present evidence of product stability and efficacy. The tender documentation will likely specify the required quantities, delivery schedules to healthcare facilities, and potentially cold chain management requirements. The evaluation criteria will heavily emphasize product quality, regulatory compliance, supplier reliability, the ability to ensure continuity of supply, and competitive pricing. Experience in supplying similar biologic therapies will be advantageous.

Data provenance

This notice is sourced from Belgium e-Procurement and was originally published on October 7, 2026. Last refreshed today. Original language: French. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About Healthcare Public Procurement (HeCaPP)

Healthcare Public Procurement (HeCaPP) has issued 67 procurement notices on BidsFactory, including 6 currently open and 28 awarded contracts. Activity concentrates in Health & Medical, Industry & Manufacturing, and Information & Communication Technology. All notices are published for Belgium. Notices are distributed via Belgium e-Procurement and TED - Tenders Electronic Daily (EU). Most recent publication: October 7, 2026.

Frequently asked questions about this tender

How can I submit a bid?

Visit Belgium e-Procurement to access the full notice, required documents, and submission instructions provided by the contracting authority.

Who is the contracting authority?

This notice was issued by Healthcare Public Procurement (HeCaPP) in Belgium. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

What type of contract is this?

This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

Where will the contract be performed?

The contract is for delivery in Belgium. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.